Skip to main content

A new antifungal drug works in a surprising way

Mandimycin soaks up molecules that all forms of life share, yet appears to target only fungi

A growing colony of fungi forms an irregular white blob in the center of an orange colored growth medium in a petri dish. That fungi may be no match for a newfound bacterial compound called Mandimycin that holds promise as an antifungal drug.

Fungi, like this colony growing in a lab dish, are notoriously hard to treat. A newly discovered compound made by bacteria kills even fungi that are resistant to other antifungal drugs. The compound may one day become a drug — if scientists can figure out why it doesn't also kill human cells and bacteria.

TopMicrobialStock/iStock/Getty Images Plus

A newly discovered bacterial weapon against fungi can kill even drug-resistant strains, raising hopes for a new antifungal drug.

Fungal infections have been spreading rapidly and widely in recent years, fueled in part by climate change. Some fungi, including Candida auris, have developed resistance to some highly effective antifungal drugs which have been in use for decades. So scientists have been searching for new drugs to keep fungi in check.

Researchers in China may have found a new type of antifungal called mandimycin, the team reports March 19 in Nature. Mandimycin killed fungal infections in mice more effectively than amphotericin B and several other commonly used antifungal drugs. It even worked against resistant C. auris strains.

Bacteria are masters at fending off fungi, says Martin Burke, a chemist at the University of Illinois Urbana-Champaign. “There’s been this war raging for 2 billion years,” he says. Bacteria and fungi have been “building weapons to try to compete with each other for nutrients in the environment.” Humans have been spying on both armies to learn how to make antibiotics and antifungal drugs. 

In one such mission, Zongqiang Wang of China Pharmaceutical University in Nanjing and colleagues combed more than 300,000 bacterial genomes looking for possible weapons against fungi. One strain of Streptomyces netropsis contained a cluster of genes that encode enzymes for building the compound mandimycin.

The antifungal has a backbone structure similar to some other antifungal drugs but has two sugar molecules tacked onto its tail. Those sugars are important for how the molecule kills fungi, because they change the target that the weapon is aimed at.

Some existing antifungal drugs like amphotericin B clump together to form large spongelike structures on fungi’s cell membranes, Burke and colleagues previously found. This antifungal sponge pulls a molecule called ergosterol from the membrane faster than the fungi can make more. Ergosterol helps maintain fungal membranes’ stability, crucial for protecting a cell’s inner workings. Extracting this membrane component eventually kills the fungus. Though it’s good at killing fungi, amphotericin B has drawbacks. It can also extract cholesterol from human cells, making it toxic to kidneys.

Mandimycin may also be a sponge, Burke and Arun Maji of the University of Kentucky College of Pharmacy in Lexington speculate in a commentary also published March 19 in Nature, but it sops up different membrane components.  

Instead of ergosterol, mandimycin is attracted to phospholipids, the major building blocks of membranes, Wang and colleagues discovered. It’s the sugars on the tail that allow mandimycin to target phospholipids, particularly one called phosphatidylinositol, the team found. Removing those sugars caused mandimycin to latch on to ergosterol, though more weakly than existing antifungals.

While intact mandimycin proved to be a potent fungi killer, it was far less toxic to mice’s kidneys and to human kidney cells grown in lab dishes than amphotericin B. Bacteria escaped mandimycin unscathed.

The ability to destroy fungi but not harm human and bacterial cells has Burke puzzled.

“This is the wild part about mandimycin that I don’t understand,” he says. Why doesn’t it kill the bacteria that produce it?

Only fungi have ergosterol in their membranes, so other cells aren’t harmed by drugs that soak it up. But fungi, bacteria and mammals all have phospholipids, which means pulling those out of membranes should be damaging across the board, including to the mandimycin-making bacteria. Wang and colleagues suggest that mandimycin’s attacks might be specific to phospholipids found in fungi, but not in other types of cells.

That is just one of the mysteries researchers will need to solve before mandimycin can be tested in people, Burke says. “It’s one of those exciting papers that opens a lot of doors, [and] pretty much behind every one is another question.”

https://worldnewsguru.us/?p=26365&network_id=

Comments

Popular posts from this blog

Stocks and dollar end 2024 steady, 2025 all about Trump

By Ankur Banerjee and Alun John SINGAPORE/LONDON () -World stocks held steady on Tuesday in cautious year-end trading that has seen investors bracing for the incoming Donald Trump administration by scaling back bets on deep U.S. interest rate cuts in 2025, helping the dollar stand tall against most other currencies. Volumes were light with a holiday for the New Year looming, with the Santa-rally largely failing to materialise as elevated Treasury yields weigh on high equity valuations and boost the greenback. MSCI's world share index was flat on the day, but set to wrap up 2025 with a 16% annual gain. This year's rally has been largely a U.S. phenomenon, with the having risen around 24% compared with an 8% gain for MSCI's broadest index of Asia-Pacific shares outside Japan, and just 5% for Europe's . () But the mood latterly has been more cautious on the back of higher U.S. Treasury yields. The yield on the 10-year note reached 4.64% late last week, its highest...

Celebrity spa haunt Champneys to explore £250m sale

The proprietor of Britain's supreme-known spa hotel has known as in bankers to attend explore strategic concepts on the eve of its centenary. Sky News has learnt that Champneys has appointed Cavendish to picture it on attainable deal opportunities, including the acquisition of a recent dwelling as successfully as a sale of the enterprise. The company's net sites are known for his or her A-checklist celeb clientele, including Daniel Craig, Anthony Joshua, Kate Moss, Brad Pitt and Naomi Campbell. Money most recent: Warning for millions of mortgage borrowers Diana, Princess of Wales, used to be moreover acknowledged to be a frequent Champneys guest. The chain now contains a handful of net sites, including at Wooded space Mere in Hampshire and the everyday Henlow spa in Bedfordshire. Champneys is now understood to be in talks to finalise the addition of a further dwelling by shopping an gift spa hotel. The company used to be previously owned by the unhur...

The search for the world’s most efficient charities

Dec 19th 2024 G IVING IS BIG business. In 2023 Americans alone handed $557bn to charities, according to the Giving USA annual report. So identifying which charities are the most efficient in terms of good done per dollar given is important. GiveWell, a charity evaluator, tries to do just this, and currently recommends giving to four worthy organisations. How is this recommendation put together, and how good is it? Explore more Finance Reuse this content https://worldnewsguru.us/?p=14494&network_id=